TegoScience Inc (191420) - Net Assets
Based on the latest financial reports, TegoScience Inc (191420) has net assets worth ₩48.32 Billion KRW (≈ $32.74 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩75.05 Billion ≈ $50.86 Million USD) and total liabilities (₩26.73 Billion ≈ $18.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of TegoScience Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩48.32 Billion |
| % of Total Assets | 64.38% |
| Annual Growth Rate | 7.16% |
| 5-Year Change | 3.82% |
| 10-Year Change | 93.71% |
| Growth Volatility | 13.5 |
TegoScience Inc - Net Assets Trend (2015–2025)
This chart illustrates how TegoScience Inc's net assets have evolved over time, based on quarterly financial data. See 191420 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for TegoScience Inc (2015–2025)
The table below shows the annual net assets of TegoScience Inc from 2015 to 2025. For live valuation and market cap data, see 191420 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩50.33 Billion ≈ $34.11 Million |
+0.94% |
| 2024-12-31 | ₩49.86 Billion ≈ $33.79 Million |
+7.63% |
| 2023-12-31 | ₩46.33 Billion ≈ $31.39 Million |
-4.67% |
| 2022-12-31 | ₩48.60 Billion ≈ $32.93 Million |
+0.25% |
| 2021-12-31 | ₩48.47 Billion ≈ $32.85 Million |
-1.05% |
| 2020-12-31 | ₩48.99 Billion ≈ $33.20 Million |
+2.45% |
| 2019-12-31 | ₩47.82 Billion ≈ $32.41 Million |
+2.44% |
| 2018-12-31 | ₩46.68 Billion ≈ $31.63 Million |
+30.70% |
| 2017-12-31 | ₩35.71 Billion ≈ $24.20 Million |
+37.47% |
| 2016-12-31 | ₩25.98 Billion ≈ $17.61 Million |
+3.06% |
| 2015-12-31 | ₩25.21 Billion ≈ $17.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to TegoScience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 91.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.05 Billion | 2.08% |
| Other Components | ₩49.45 Billion | 97.92% |
| Total Equity | ₩50.51 Billion | 100.00% |
TegoScience Inc Competitors by Market Cap
The table below lists competitors of TegoScience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beshom Holdings Bhd
KLSE:7668
|
$40.95 Million |
|
SIFCO Industries Inc
NYSE MKT:SIF
|
$40.95 Million |
|
Connexa Sports Technologies Inc.
NASDAQ:YYAI
|
$40.96 Million |
|
NH SPAC 5
KQ:215790
|
$40.98 Million |
|
Econpile Holdings Bhd
KLSE:5253
|
$40.93 Million |
|
LFE Corporation Bhd
KLSE:7170
|
$40.92 Million |
|
Timberwell Bhd
KLSE:7854
|
$40.91 Million |
|
Thai Textile Industry Public Company Limited
BK:TTI
|
$40.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TegoScience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 49,859,800,040 to 50,507,213,680, a change of 647,413,640 (1.3%).
- Net loss of 7,012,425,950 reduced equity.
- Other factors increased equity by 7,659,839,590.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.01 Billion | -13.88% |
| Other Changes | ₩7.66 Billion | +15.17% |
| Total Change | ₩- | 1.30% |
Book Value vs Market Value Analysis
This analysis compares TegoScience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.13x to 1.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3508.18 | ₩7480.00 | x |
| 2017-12-31 | ₩4537.53 | ₩7480.00 | x |
| 2018-12-31 | ₩5781.08 | ₩7480.00 | x |
| 2019-12-31 | ₩5914.00 | ₩7480.00 | x |
| 2020-12-31 | ₩6092.89 | ₩7480.00 | x |
| 2021-12-31 | ₩6045.63 | ₩7480.00 | x |
| 2022-12-31 | ₩6069.56 | ₩7480.00 | x |
| 2023-12-31 | ₩5803.17 | ₩7480.00 | x |
| 2024-12-31 | ₩6227.36 | ₩7480.00 | x |
| 2025-12-31 | ₩6308.22 | ₩7480.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TegoScience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -118.04%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.55x
- Recent ROE (-13.88%) is below the historical average (-1.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 5.84% | 19.67% | 0.29x | 1.02x | ₩-1.05 Billion |
| 2016 | 2.97% | 9.25% | 0.19x | 1.72x | ₩-1.83 Billion |
| 2017 | -16.86% | -69.67% | 0.18x | 1.33x | ₩-9.59 Billion |
| 2018 | -3.91% | -23.26% | 0.17x | 1.02x | ₩-6.49 Billion |
| 2019 | 1.79% | 13.48% | 0.13x | 1.02x | ₩-3.93 Billion |
| 2020 | 3.78% | 21.07% | 0.17x | 1.03x | ₩-3.05 Billion |
| 2021 | 0.29% | 1.68% | 0.16x | 1.05x | ₩-4.71 Billion |
| 2022 | 0.54% | 3.44% | 0.15x | 1.06x | ₩-4.60 Billion |
| 2023 | -5.00% | -29.88% | 0.16x | 1.05x | ₩-6.97 Billion |
| 2024 | 6.72% | 49.56% | 0.13x | 1.05x | ₩-1.64 Billion |
| 2025 | -13.88% | -118.04% | 0.08x | 1.55x | ₩-12.06 Billion |
Industry Comparison
This section compares TegoScience Inc's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $84,654,166,830
- Average return on equity (ROE) among peers: -2.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TegoScience Inc (191420) | ₩48.32 Billion | 5.84% | 0.55x | $40.93 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.82 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $37.74 Billion | 28.99% | 1.00x | $26.85 Million |
| NatureCell Co.Ltd (007390) | $57.16 Billion | -11.92% | 0.64x | $1.10 Billion |
| Sam-A Pharm. Co. Ltd (009300) | $156.10 Billion | 3.72% | 0.08x | $57.12 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $228.48 Billion | -9.06% | 0.28x | $82.40 Million |
| WooGene B&G Co. Ltd (018620) | $27.27 Billion | -46.89% | 2.12x | $47.60 Million |
| Oscotec Inc (039200) | $46.29 Billion | 7.50% | 0.52x | $755.10 Million |
| EstechPharma Co. Ltd (041910) | $72.13 Billion | -1.21% | 0.27x | $40.76 Million |
| Komipharm International Co. Ltd (041960) | $76.13 Billion | -8.60% | 0.75x | $338.89 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $30.93 Billion | 3.34% | 0.42x | $26.52 Million |
About TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.